SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 06 2021
10 06 2021
Historique:
received:
19
11
2020
accepted:
17
05
2021
entrez:
11
6
2021
pubmed:
12
6
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Lombardy is the Italian region most affected by COVID-19. We tested the presence of plasma anti-SARS-CoV-2 IgG antibodies in 3985 employees across 7 healthcare facilities in areas of Lombardy with different exposure to the SARS-CoV-2 epidemic. Subjects filled a questionnaire to self-report on COVID-19 symptoms, comorbidities, smoking, regular or remote working, and the exposure to COVID-infected individuals. We show that the number of individuals exposed to the virus depended on the geographical location of the facility, ranging between 3 and 43%, consistent with the spatial variation of COVID-19 incidence in Lombardy, and correlated with family interactions. We observed a higher prevalence of females than males positive for IgG, however the level of antibodies was similar, suggesting a comparable magnitude of the anti-spike antibody response. IgG positivity among smokers was lower (7.4% vs 13.5%) although without difference in IgG plasma levels. We observed 11.9% of IgG positive asymptomatic individuals and another 23.1% with one or two symptoms. Interestingly, among the IgG positive population, 81.2% of subjects with anosmia/dysgeusia and fever were SARS-CoV-2 infected, indicating that these symptoms are strongly associated to COVID-19. In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection is dependent on the geographical exposure to the virus and primarily to family rather than hospital exposure.
Identifiants
pubmed: 34112899
doi: 10.1038/s41598-021-91773-4
pii: 10.1038/s41598-021-91773-4
pmc: PMC8192543
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12312Subventions
Organisme : Italian Ministry of Health
ID : Ricerca corrente
Références
ERJ Open Res. 2020 Jul 13;6(2):
pubmed: 32685435
Vaccines (Basel). 2020 Aug 23;8(3):
pubmed: 32842505
JAMA. 2020 Jun 16;323(23):2425-2427
pubmed: 32421144
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
JAMA. 2020 Jun 9;323(22):2340-2341
pubmed: 32401274
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32430429
Nat Rev Immunol. 2020 Jun;20(6):375-388
pubmed: 32132681
Int J Infect Dis. 2020 Sep;98:287-289
pubmed: 32634587
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
Intern Emerg Med. 2020 Aug;15(5):845-852
pubmed: 32385628
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
Radiology. 2020 Aug;296(2):E41-E45
pubmed: 32049601
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Clin Chem Lab Med. 2020 Jun 25;58(7):1070-1076
pubmed: 32172228
J Hepatol. 2020 Nov;73(5):1063-1071
pubmed: 32526252
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
J Med Virol. 2020 Jul;92(7):903-908
pubmed: 32219885
Elife. 2020 May 11;9:
pubmed: 32392129
EClinicalMedicine. 2021 Mar;33:100770
pubmed: 33718853
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652
Vaccines (Basel). 2020 Sep 16;8(3):
pubmed: 32947988